Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Frederick L. Locke, Justin Chou, Saran Vardhanabhuti, Regis Perbost, Peter Dreger, Brian T Hill, Catherine Lee, Pier Luigi Zinzani, Nicolaus Kroeger, Armando López-Guillermo, Hildegard Greinix, Wangshu Zhang, Gayatri Tiwari, Christina Ann To, Paul C. Cheng, Adrian Bot, Rhine Shen, Simone Filosto, Jerome Galon
Institutions: Moffitt Cancer Center, Kite (United States), Heidelberg University, University Hospital Heidelberg, Cleveland Clinic, University of Utah, Huntsman Cancer Institute, University of Bologna, University Medical Center Hamburg-Eppendorf, Hospital Clínic de Barcelona, University of Graz, Medical University of Graz, Inserm, Sorbonne Université, Centre de Recherche des Cordeliers, Laboratoire d’immunologie intégrative du cancer
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281838775